Literature DB >> 28829719

Cost effectiveness of a practice-based intervention to improve vaccination rates in adults less than 65-years-old.

Kenneth J Smith1, Mary Patricia Nowalk2, Chyongchiou J Lin2, Richard K Zimmerman2.   

Abstract

The cost-effectiveness of the 4 Pillars™ Practice Transformation Program to improve vaccination rates in adults <65-years-old is unknown. Two vaccines, influenza and Tdap (tetanus, diphtheria, acellular pertussis), were targeted for this age group. Cost-effectiveness of the intervention compared with control, with a primary outcome of cost per quality adjusted life year (QALY) gained, was estimated from societal and third party payer perspectives over a 10-year time horizon using a decision analysis model. Vaccination rates and intervention costs were derived from an intervention trial, and vaccine effectiveness, illness rates, and costs with/without vaccination were obtained from US databases and literature data. Future costs and effectiveness were discounted at 3%/year. The intervention cost was $1.78 per eligible patient/year. From the societal perspective, per patient total vaccination and illness costs with the intervention were $27.43 higher than control while gaining 0.00087 QALYs, costing $31,700/QALY gained. The intervention, extrapolated to the US population, could prevent 4.2 million cases, 87,489 hospitalizations, and 5,680 deaths due to influenza over 10 y in adults <65-years-old. In a probabilistic sensitivity analysis, the intervention was favored in 68.2% of model runs at a $50,000/QALY level and in 94.3% at $100,000/QALY. In a separate scenario analysis, the intervention became cost saving if influenza economic burden was >$2,099 per case (societal base case $846). Thus, the 4 Pillars Practice Transformation Program is an economically reasonable intervention to improve vaccination rates in adults <65-years-old, and could have a substantial public health impact.

Entities:  

Keywords:  adult vaccination; cost-effectiveness analysis; influenza vaccination; pertussis vaccination

Mesh:

Substances:

Year:  2017        PMID: 28829719      PMCID: PMC5647965          DOI: 10.1080/21645515.2017.1356526

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  22 in total

1.  Pertussis in adolescents and adults: should we vaccinate?

Authors:  Grace M Lee; Charles Lebaron; Trudy V Murphy; Susan Lett; Stephanie Schauer; Tracy A Lieu
Journal:  Pediatrics       Date:  2005-06       Impact factor: 7.124

2.  The annual impact of seasonal influenza in the US: measuring disease burden and costs.

Authors:  Noelle-Angelique M Molinari; Ismael R Ortega-Sanchez; Mark L Messonnier; William W Thompson; Pascale M Wortley; Eric Weintraub; Carolyn B Bridges
Journal:  Vaccine       Date:  2007-04-20       Impact factor: 3.641

3.  Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold.

Authors:  Peter J Neumann; Joshua T Cohen; Milton C Weinstein
Journal:  N Engl J Med       Date:  2014-08-28       Impact factor: 91.245

Review 4.  Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis.

Authors:  Michael T Osterholm; Nicholas S Kelley; Alfred Sommer; Edward A Belongia
Journal:  Lancet Infect Dis       Date:  2011-10-25       Impact factor: 25.071

5.  Cluster randomized trial of a toolkit and early vaccine delivery to improve childhood influenza vaccination rates in primary care.

Authors:  Richard K Zimmerman; Mary Patricia Nowalk; Chyongchiou Jeng Lin; Kristin Hannibal; Krissy K Moehling; Hsin-Hui Huang; Annamore Matambanadzo; Judith Troy; Norma J Allred; Greg Gallik; Evelyn C Reis
Journal:  Vaccine       Date:  2014-04-29       Impact factor: 3.641

6.  Cost-Effectiveness of the 4 Pillars Practice Transformation Program to Improve Vaccination of Adults Aged 65 and Older.

Authors:  Kenneth J Smith; Richard K Zimmerman; Mary Patricia Nowalk; Chyongchiou J Lin
Journal:  J Am Geriatr Soc       Date:  2016-12-26       Impact factor: 5.562

7.  Success of the 4 pillars toolkit for influenza and pneumococcal vaccination in adults.

Authors:  Mary Patricia Nowalk; Beth A D Nolan; Jean Nutini; Faruque Ahmed; Steven M Albert; Michael Susick; Richard K Zimmerman
Journal:  J Healthc Qual       Date:  2013-06-18       Impact factor: 1.095

8.  Surveillance of Vaccination Coverage Among Adult Populations - United States, 2014.

Authors:  Walter W Williams; Peng-Jun Lu; Alissa O'Halloran; David K Kim; Lisa A Grohskopf; Tamara Pilishvili; Tami H Skoff; Noele P Nelson; Rafael Harpaz; Lauri E Markowitz; Alfonso Rodriguez-Lainz; Carolyn B Bridges
Journal:  MMWR Surveill Summ       Date:  2016-02-05

9.  2014-2015 Influenza Vaccine Effectiveness in the United States by Vaccine Type.

Authors:  Richard K Zimmerman; Mary Patricia Nowalk; Jessie Chung; Michael L Jackson; Lisa A Jackson; Joshua G Petrie; Arnold S Monto; Huong Q McLean; Edward A Belongia; Manjusha Gaglani; Kempapura Murthy; Alicia M Fry; Brendan Flannery
Journal:  Clin Infect Dis       Date:  2016-10-04       Impact factor: 20.999

10.  Estimated influenza illnesses and hospitalizations averted by vaccination--United States, 2013-14 influenza season.

Authors:  Carrie Reed; Inkyu Kevin Kim; James A Singleton; Sandra S Chaves; Brendan Flannery; Lyn Finelli; Alicia Fry; Erin Burns; Paul Gargiullo; Daniel Jernigan; Nancy Cox; Joseph Bresee
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2014-12-12       Impact factor: 17.586

View more
  3 in total

1.  Cost-Effectiveness of Pneumococcal Vaccination and Uptake Improvement Programs in Underserved and General Population Adults Aged < 65 Years.

Authors:  Angela R Wateska; Mary Patricia Nowalk; Chyongchiou J Lin; Lee H Harrison; William Schaffner; Richard K Zimmerman; Kenneth J Smith
Journal:  J Community Health       Date:  2020-02

2.  Cost-Effectiveness of Pneumococcal Vaccination Policies and Uptake Programs in US Older Populations.

Authors:  Angela R Wateska; Mary Patricia Nowalk; Chyongchiou J Lin; Lee H Harrison; William Schaffner; Richard K Zimmerman; Kenneth J Smith
Journal:  J Am Geriatr Soc       Date:  2020-02-22       Impact factor: 5.562

3.  Is further research on adult pneumococcal vaccine uptake improvement programs worthwhile? Α value of information analysis.

Authors:  Angela R Wateska; Mary Patricia Nowalk; Hawre Jalal; Chyongchiou J Lin; Lee H Harrison; William Schaffner; Richard K Zimmerman; Kenneth J Smith
Journal:  Vaccine       Date:  2021-05-25       Impact factor: 4.169

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.